title: Nuclear gene targeting using negatively charged liposomes.
abstract: Oligonucleotides are a very useful tool to control gene activity. Oligos work by complementary base-pairing with target sequences either in the nucleus or in the cytosol (Zelphati, O., Szoka, F.C., Jr., 1996. Liposomes as a carrier for intracellular delivery of antisense oligonucleotides: a real or magic bullet? J. Contr. Rel. 41, 99-119). In a new approach using chimeric oligonucleotides (Yoon, K., Cole Strauss, A., Kmiec, E.B., 1996. Targeted gene correction of episomal DNA in mammalian cells mediated by a chimeric RNA-DNA oligonucleotide. Proc. Natl. Acad. Sci. USA 93, 2071-2076) conversion of single base mutations with help of intranuclear repair mechanisms maybe an advantageous method to cure genetic diseases which are based on single point mutations. These chimeric oligonucleotides are constructed in a way that they form an intramolecular double strand of DNA and modified RNA-bases. We used a fluorescent labelled pure 68-mer DNA-analogue of a chimeric oligonucleotides to follow the intracellular fate of these kind of genetic material. The oligos were complexed with protamine sulfate and coated with three different liposomal formulations. The AVE-3 formulation shows enhanced properties compared to a classical neutral and negatively charged formulation. Nuclear localisation of oligos could only be observed with the AVE-3 formulation. Furthermore only the negatively charged liposome formulations interact with the protamine-complexed oligonucleotides.
authors.affiliation: Department of Pharmaceutics and Biopharmacy, Philipps University, Ketzerback 63, Marburg, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Welz
authors.forename: W
authors.initials: W
authors.lastname: Neuhuber
authors.forename: H
authors.initials: H
authors.lastname: Schreier
authors.forename: R
authors.initials: R
authors.lastname: Repp
authors.forename: W
authors.initials: W
authors.lastname: Rascher
authors.forename: A
authors.initials: A
authors.lastname: Fahr
mesh_terms: D001692:Biological Transport; D002467:Cell Nucleus / Q000235:genetics / Q000378:metabolism*; D004339:Drug Compounding; D005452:Fluoresceins; D018390:Gene Targeting; D006801:Humans; D008081:Liposomes / Q000737:chemistry / Q000235:genetics / Q000493:pharmacokinetics*; D009841:Oligonucleotides / Q000737:chemistry / Q000235:genetics / Q000493:pharmacokinetics; D011479:Protamines / Q000737:chemistry / Q000235:genetics / Q000493:pharmacokinetics; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D005452:Fluoresceins; D008081:Liposomes; D009841:Oligonucleotides; D011479:Protamines